Document › Details
MorphoSys AG. (3/16/11). "Press Release: MorphoSys Signs Manufacturing Agreement with Boehringer Ingelheim".
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and Boehringer Ingelheim announced today the signing of a biopharmaceutical manufacturing agreement for therapeutic antibodies. The agreement covers the process development and manufacturing of additional clinical material for MorphoSys's proprietary MOR208 program and other drug candidates. MOR208, a potent monoclonal anti-CD19 antibody, is in development for the treatment of chronic lymphocytic leukemia and potentially other B-cell malignancies. The program is currently being evaluated in a phase 1 clinical trial in the USA by MorphoSys's partner Xencor Inc.
"Adding an additional supplier to our proprietary development set-up will help to prevent any bottlenecks in clinical trial supply in the years ahead", commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "Additionally, establishing a commercial manufacturing process with Boehringer Ingelheim early in the development of MOR208 will clearly increase the value of this program."
Simon Sturge, Corporate Senior Vice President of the Biopharmaceuticals Division at Boehringer Ingelheim, said: "We believe that the combination of MorphoSys's successful track record in the discovery and clinical development of antibody-based therapeutics and our proven competence in technical development and manufacturing will be an optimal fit. We look forward to supporting the team at MorphoSys with robust manufacturing processes for clinic and market supply."
"Boehringer Ingelheim is a world-class contract manufacturing organization and we are delighted to sign this agreement with them today", commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG. "Our proprietary pipeline currently comprises eight fully-owned therapeutic antibodies in addition to two co-development candidates selected within the Novartis alliance. With MOR103, a HuCAL-based anti-inflammatory antibody targeting GM-CSF, and MOR202, a HuCAL-based cancer antibody targeting CD38, as well as MOR208, we will investigate three proprietary drug programs in clinical trials in 2011."
MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM-CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visit http://www.morphosys.com/
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay® and RapMAT® are registered trademarks of MorphoSys; arYlaTM is a trademark of MorphoSys.
About Boehringer Ingelheim:
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees. Since it was founded in 1885, the family-owned company has been committed for 125 years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
Today, Boehringer Ingelheim is one of the world's leading companies for contract development and manufacture of biopharmaceuticals. All types of services from mammalian cell line or microbial strain development to final drug production can be delivered within a one-stop-shop concept. Boehringer Ingelheim delivers services for pre-clinical development up to global market supply with a strong commitment to its customers at its manufacturing facilities for mammalian cell culture and microbial fermentation. Boehringer Ingelheim has brought 18 molecules to market and has many years of experience in multiple molecule classes such as monoclonal antibodies, recombinant proteins, interferons, enzymes, fusion molecules and plasmid DNA. Furthermore, high-titer platform technologies for new antibody mimetic formats such as scaffold proteins and antibody fragments are available for the manufacture of customer products. Contact us: email@example.com
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
For more information, please contact:
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
Media + PR
+49 6132 77 3966
Record changed: 2014-04-24
More documents for MorphoSys (Group)
-  MorphoSys AG. (12/15/14). "Press Release: MorphoSys's MOR208 Program Receives Positive Opinion for Orphan Medicinal Product Designation from EMA for DLBCL"....
-  MorphoSys AG. (12/8/14). "Press Release: MorphoSys Presents Updated Phase 2 Clinical Results for MOR208 Monotherapy in NHL at American Society of Hematology Meeting. DLBCL and FL Identified as Particularly Promising Indications"....
-  MorphoSys AG. (11/7/14). "Press Release: MorphoSys AG Reports Results for the First Nine Months of 2014. Increased EBIT Guidance Confirmed"....
-  MorphoSys AG. (10/22/14). "Press Release: MorphoSys to Receive Milestone Payment for Guselkumab Phase 3 Program"....
-  MorphoSys AG. (10/15/14). "Press Release: MorphoSys Acquires Lanthipeptide Technology from Lanthio Pharma"....
-  MorphoSys AG. (9/15/14). "Press Release: MorphoSys Receives Research Grant to Develop Novel Therapeutic Antibodies Targeting GPCRs"....
-  MorphoSys AG. (8/19/14). "Press Release: MorphoSys and Emergent BioSolutions Sign License Agreement to Co-develop and Commercialize Prostate Cancer Drug Candidate ES414"....
-  MorphoSys AG. (7/28/14). "Press Release: MorphoSys AG Reports Results for the First Six Months of 2014"....
-  MorphoSys AG. (7/23/14). "Press Release: MorphoSys and Galapagos Advance Joint Antibody Program in Inflammatory Disease into Preclincal Development"....
-  MorphoSys AG. (6/12/14). "Press Release: MorphoSys and Merck Serono Enter Strategic Immuno-oncology Collaboration"....
To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to firstname.lastname@example.org and simply fill the subject line with the word »LSG newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)